Efficacité clinique et biologique du tocilizumab au cours de la maladie de Horton : à propos de trois observations et revue de la littérature

Abstract

IntroductionTreatment of giant cell arteritis is based on prolonged corticosteroid therapy but adverse side effects are common especially in the elderly. Case reportsWe report three patients with giant cell vasculitis treated by tocilizumab, an interleukin-6 receptor antibody, owing to resistance or intolerance to corticosteroid therapy. A favorable outcome was rapidly observed both on clinical and biological data allowing a corticoid therapy sparing. ConclusionTocilizumab is a promising treatment of giant cell arteritis but controlled trials are needed to confirm its efficacy.